Electromagnetic Fields
Also known as: EMFs
Methodology & AI Transparency ⓘ
Electromagnetic Fields Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Electric and magnetic fields (EMFs), also called radiation , are areas of energy that surround electrical devices.
- 2 Real-world patient consensus: Diagnostic registry C81.7: Electromagnetic Fields is managed within Cancer & Oncology (aka EMFs).
- 3 Typical cash cost range: Differential triage of Electromagnetic Fields (C81.7) utilizes radiation) paired with in Electromagnetic Fields (C81.7: proactive supportive symptom).
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Electromagnetic Fields (C81.7): Pathology / Molecular in Electromagnetic Fields (C81.7: Genomic Staging) & Complete Blood Count in Electromagnetic Fields (C81.7: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C81.7)).
Ask our AI Specialists anything about Electromagnetic Fields
What Is Electromagnetic Fields?
Electric and magnetic fields (EMFs), also called radiation , are areas of energy that surround electrical devices. Everyday sources of EMFs include: Power lines Electrical wiring Microwave ovens Computers Cell phones Some people worry about EMF exposure and cancer. Some studies have found a link between EMF exposure and a higher risk of childhood leukemia, but other studies have not. Other studies have not found proof that EMF exposure causes other childhood cancers. Studies in adults did not prove that EMF exposure causes cancer. Some people worry that cell (wireless) phones cause cancer or other health problems.
Pathophysiology, Underlying Causes & Clinical Presentation
Electromagnetic Fields (C81.7) alters cancer & oncology homeostasis through microenvironment inflammation [Electromagnetic Fields C81.7]; Cross-referenced with NIH MeSH (Electromagnetic Fields), clinical remission targets Complete Blood Count in Electromagnetic Fields (C81.7: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C81.7).
Common Symptoms & Clinical Signs
- • Reducing the amount of time you spend using your cell phone
- • Use speaker mode or a headset to place more distance between your head and the cell phone
- • Presentation of Electromagnetic Fields (C81.7): persistent painless lump, in Electromagnetic Fields (C81.7: non-healing ulcer/mole change,)
- • Secondary Electromagnetic Fields clinical sign: unintended weight loss [Electromagnetic Fields C81.7]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Electromagnetic Fields Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C81.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Electromagnetic Fields (C81.7: Genomic Staging) | Guideline-concordant surveillance (C81.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Electromagnetic Fields (C81.7: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C81.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Electromagnetic Fields (C81.7: Organ Function Panel) | Preserved renal/hepatic clearance (C81.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Electromagnetic Fields
Treatment selection for Electromagnetic Fields depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Electromagnetic Fields)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Prognostic relation of body mass index on extended aromatase inhibition treatment: What a 3,606-Participant Study Found We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. European journal of cancer (Oxford, England : 1990) • 2025-06-03 • Phase III Randomized Trial | N = 3,606 | 90/100 | PMID 40286474 ↗ |
| Can This Approach Help? Inside the Latest Research on Real-world benefits and safety of the combination of photobiomodulation therapy A combination of PBMT and PEMF is a valid and safe treatment option for AGA. Journal of cosmetic dermatology • 2023-03-15 • Randomized Controlled Trial | N = 80 | 88/100 | PMID 36345917 ↗ |
| What the Latest Evidence Really Says About Metformin and pancreatic neuroendocrine T2DM represents a risk factor for the insurgence of pNET and is a significant predictor of poor post-treatment TFS of pNET patients. World journal of gastroenterology • 2024-02-21 • Meta-Analysis | Multi-cohort | 86/100 | PMID 38515954 ↗ |
| What the Latest Evidence Really Says About Association of Spironolactone Use With Risk of Seven studies met eligibility criteria, with sample sizes ranging from 18 035 to 2.3 million and a total population of 4 528 332 individuals (mean age, 62.6-72.0 years; in the studies without stratification by sex, women... JAMA dermatology • 2022-03-01 • Meta-Analysis | Multi-cohort | 86/100 | PMID 35138351 ↗ |
| Can This Approach Help? Inside the Latest Research on [Advanced Medical The JIPANG study failed to show the superiority of pemetrexed plus cisplatin in terms of recurrence-free survival, as primary endpoint. Gan to kagaku ryoho. Cancer & chemotherapy • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36539239 ↗ |
Electromagnetic Fields Patient Community & “People Like Me” Threads
Filter Electromagnetic Fields community threads and patient logs by age, biological sex, dosage, and treatment duration.